Scholars Central

Research articlePublished 2017

Strategic Perspectives on Improved Anti-Tumor Drug Effects in Combination with Clinically Equivalent or Lower Concentrations of Epigenetic Modifiers, DNA Methyltransferase Inhibitors, and Histone Deacetylase Inhibitors

Authors: Shuko Hakata, Kouji Okada, Jun Terashima, Toshie Gamou, Wataru Habano, Shogo Ozawa

Cancer Science & Therapy

Volume 9 · Issue 7 · Pages 541–544

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The aim of this research is to facilitate the pursuit of improved chemotherapeutic drugs in combination with epigenetic modifiers. Both in vitro studies and a clinical study have described the combinations of DNA methyltransferase inhibitors with irinotecan and histone deacetylase inhibitors with 5-fluorouracil or gemcitabine to enhance their anti-cancer activities. The molecular mechanisms involved in the potentiation of anti-tumor activities were apoptosis regulation, cellular metabolism, DNA topoisomerase-I upregulation, cell-cell adhesion, regulation of transcription (DNA-templated), DNA repair, and the PI3K/AKT signaling pathway. More importantly, the priming effects and long-lasting effects induced by DNA methyltransferase inhibitors, when applied as a pretreatment, sensitized cancer cells to subsequent anti-cancer drug treatments. The combinations of 5-fluorouracil and gemcitabine with histone deacetylase inhibitors (depsipeptide and valproic acid, respectively), increased the expression of major histocompatibility complex class II, which may warrant further investigation for possible accurate biomarkers and therapeutic targets. As valproic acid downregulated histone deacetylase in patients recruited in a clinical phase I/II study, the activity of valproic acid may be associated with the enhanced anti-tumor activity in combination with 5-fluorouracil. This research provides a positive perspective on the combination therapy of anticancer drugs with epigenetic modifiers.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Shuko Hakata”
  • BylineArticles whose byline prints “Kouji Okada”
  • BylineArticles whose byline prints “Jun Terashima”
  • BylineArticles whose byline prints “Toshie Gamou”
  • BylineArticles whose byline prints “Wataru Habano”
  • BylineArticles whose byline prints “Shogo Ozawa”